STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[8-K] Health Catalyst, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Health Catalyst (HCAT) furnished a press release announcing its financial results for the quarter ended September 30, 2025. The company attached the full release and a Q3 2025 earnings summary as Exhibit 99.1 and Exhibit 99.2, respectively. The materials are being furnished under Item 2.02 and are not deemed filed under the Exchange Act.

Positive
  • None.
Negative
  • None.
FALSE000163642200016364222025-11-102025-11-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________________________________________
FORM 8-K
__________________________________________________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 10, 2025
__________________________________________________________
HEALTH CATALYST, INC.
(Exact name of registrant as specified in its charter)
________________________________________________________________
Delaware001-3899345-3337483
(State or other jurisdiction of
incorporation)
(Commission File Number)(IRS Employer
Identification No.)
10897 South River Front Parkway #300
South Jordan, UT 84095
(Address of principal executive offices, including zip code)

(801) 708-6800
(Registrant’s telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)
______________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 
     Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 
     Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 
     Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 
     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
______________________________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of exchange on which registered
Common Stock, par value $0.001 per shareHCATThe Nasdaq Global Select Market
________________________________________________________
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 ((§240.12b-2 of this chapter).
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.








Item 2.02. Results of Operations and Financial Condition.

On November 10, 2025, Health Catalyst, Inc. (the “Company”) issued a press release relating to its financial results for the quarter ended September 30, 2025. A copy of the press release and the Q3 2025 earnings release summary are attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and are each incorporated herein by reference.

The foregoing information (including Exhibits 99.1 and 99.2 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.
Exhibit No.Description
99.1*
Health Catalyst, Inc. press release for quarterly financial results, dated November 10, 2025
99.2*
Q3 2025 Earnings Release Summary
104Cover page Interactive Data File (embedded within the Inline XBRL document)

* Furnished herewith.


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
HEALTH CATALYST, INC.
Date: November 10, 2025
By:/s/ Jason Alger
Jason Alger
Chief Financial Officer


FAQ

What did HCAT disclose in this 8-K?

HCAT furnished a press release and an earnings release summary for its Q3 2025 financial results under Item 2.02.

Which exhibits were included with HCAT’s Q3 2025 disclosure?

The company attached Exhibit 99.1 (press release) and Exhibit 99.2 (Q3 2025 earnings release summary).

Are the Q3 2025 materials considered filed or furnished?

They are being furnished and are not deemed filed for purposes of Section 18 of the Exchange Act.

What period do the results cover for HCAT?

The results relate to the quarter ended September 30, 2025.

What is HCAT’s trading symbol and exchange?

HCAT trades on The Nasdaq Global Select Market under the symbol HCAT.
Health Catalyst

NASDAQ:HCAT

HCAT Rankings

HCAT Latest News

HCAT Latest SEC Filings

HCAT Stock Data

200.56M
66.42M
3.52%
79.72%
7.46%
Health Information Services
Services-computer Programming, Data Processing, Etc.
Link
United States
SOUTH JORDAN